GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Common Stock

Pharmala Biotech Holdings (XCNQ:MDMA) Common Stock : C$5.26 Mil (As of Feb. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Common Stock?

Pharmala Biotech Holdings's quarterly common stock increased from Aug. 2023 (C$5.14 Mil) to Nov. 2023 (C$5.26 Mil) but then stayed the same from Nov. 2023 (C$5.26 Mil) to Feb. 2024 (C$5.26 Mil).

Pharmala Biotech Holdings's annual common stock increased from Aug. 2021 (C$2.20 Mil) to Aug. 2022 (C$4.83 Mil) and increased from Aug. 2022 (C$4.83 Mil) to Aug. 2023 (C$5.14 Mil).


Pharmala Biotech Holdings Common Stock Historical Data

The historical data trend for Pharmala Biotech Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Common Stock Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
Common Stock
2.20 4.83 5.14

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.83 5.14 5.14 5.26 5.26

Pharmala Biotech Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.
Executives
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer
Fraser Macdonald Director

Pharmala Biotech Holdings Headlines

No Headlines